Market for Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
−Removed: Prior to February 3, 2020, our Common Stock, par value $0.0001 per share, was traded on the Nasdaq Capital Market under the symbol “BIOS”.
−Removed: On February 3, 2020, we changed our symbol to “OPCH” and began trading on the Nasdaq Global Select Market.
+Added: Our Common Stock, par value $0.0001 per share, is traded on the Nasdaq Global Select Market under the symbol “OPCH”.
Holders of Record
−Removed: As of March 8, 2021, there were 142 stockholders of record of our Common Stock.
+Added: As of February 18, 2022 , there were 122 stockholders of record of our Common Stock.
Dividend Policy
13 unchanged sentences
* $100 invested on December 31, 2016 in stock or index, including reinvestment of dividends.
−Removed: Selected Financial Data
−Removed: The selected consolidated financial data presented below should be read in conjunction with, and is qualified in its entirety by reference to, Management’s Discussion and Analysis of Financial Condition and Results of Operations and our consolidated financial statements and the Notes thereto appearing elsewhere in this Annual Report.
−Removed: The selected consolidated financial data for the years ended December 31, 2020, 2019 and 2018 reflect the adoption of ASU 2014-09, Revenue from Contracts with Customers (“ASC 606”) and the selected financial data for the year ended December 31, 2020 and 2019 reflect the adoption of ASU 2016-02, Leases (“ASC 842”).
−Removed: See Note 2, Summary of Significant Accounting Policies within the consolidated financial statements included in Item 8 of this report for further discussion on our accounting policies related to revenue and leases.
−Removed: The below periods include the results of operations from BioScrip, Inc.
−Removed: from the August 6, 2019 Merger Date onward.
−Removed: 2020 2019 2018 2017 2016
−Removed: (in thousands)
−Removed: Consolidated Balance Sheets Data:
−Removed: Working capital (1) (2) $ 222,989 $ 228,650 $ 227,428 $ 226,535 $ 227,763
−Removed: Total assets (2) 2,647,439 2,589,547 1,428,211 1,429,542 1,405,285
−Removed: Total debt, net 1,124,353 1,286,496 539,375 540,346 541,500
−Removed: Stockholders' equity 1,015,724 906,827 602,825 606,105 600,770
−Removed: (1) Working capital consists of total current assets less total current liabilities.
−Removed: (2) Working capital and total assets for the year ended December 31, 2020 and 2019 reflect the adoption of ASU 2016-02, Leases , and are, therefore, not comparable to prior periods.
−Removed: See Note 2, Summary of Significant Accounting Policies included in Item 8 of this report for further discussion on our accounting policies related to leases.
−Removed: Year Ended December 31,
−Removed: 2018 2017 2016
−Removed: (in thousands)
−Removed: Consolidated Statements of Comprehensive Income (Loss)
−Removed: Net revenue (2) $ 3,032,610 $ 2,310,417 $ 1,939,791 $ 1,828,046 $ 1,711,438
−Removed: Gross profit (2) 682,264 512,999 422,215 445,999 449,307
−Removed: Operating income (loss) 110,755 (319) 38,269 27,279 52,448
−Removed: Net (loss) income (8,076) (75,920) (6,115) 3,878 3,910
−Removed: Net comprehensive (loss) income (12,053) (83,959) (5,341) 3,936 3,910
−Removed: Net (loss) earnings per share, basic and diluted (0.04) (0.49) (0.04) 0.03 0.03
−Removed: Weighted average common shares outstanding, basic and diluted 180,971 156,280 142,614 142,614 142,614
−Removed: (1) 2020 and 2019 include the results of operations of BioScrip from August 6, 2019 onward and are, therefore, not comparable to prior periods.
−Removed: (2) Net revenue and gross profit for the years ended December 31, 2020, 2019 and 2018 reflect the adoption of ASU 2014-09, Revenue from Contracts with Customers , and are, therefore, not comparable to prior periods.
−Removed: See Note 2, Summary of Significant Accounting Policies included in Item 8 of this report for further discussion on our accounting policies related to revenue.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.